Markets:

Overview

News

Currencies

International

Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

49.95 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

39 40 Next >

Why Is Provention Biosciences (PRVB) Stock Up 25% Today? ↗

November 03, 2022

Provention Biosciences shares are trending after reporting earnings. PRVB stock is also up 25% on hopes of FDA approval for teplizumab.

Via InvestorPlace

Tesla Shifts China Factory Workers To US Plant, Complete European Approval For AstraZeneca's COVID-19 Shot, Tesla Eyes Cybertruck Commercialization From Next Year: Top Stories Tuesday, Nov. 01 ↗

November 01, 2022

Bloomberg Tesla Migrates Shanghai Factory Workers To Boost US Plant Production

Via Benzinga

Sanofi (SNY) Q3 2022 Earnings Call Transcript ↗

October 28, 2022

SNY earnings call for the period ending September 30, 2022.

Via The Motley Fool

Sanofi Jumps As Strong Third-Quarter Profit Leads To Guidance Boost ↗

October 28, 2022

Sanofi stock jumped Friday after the company reported better-than-expected profit.

Via Investor's Business Daily

Dupixent, Flu Vaccine Demand Boost Sanofi's Q3 Earnings, Lifts Annual Outlook ↗

October 28, 2022

Via Benzinga

Sanofi In-Licenses Preclinical Genetic Disease Candidate From An Unknown Biotech ↗

October 04, 2022

Via Benzinga

Sanofi: Q3 Earnings Insights ↗

October 28, 2022

Sanofi (NASDAQ:SNY) reported its Q3 earnings results on Friday, October 28, 2022 at 05:00 AM. Here's what investors need to know about the announcement. Earnings Sanofi beat estimated earnings by...

Via Benzinga

Earnings Scheduled For October 28, 2022 ↗

October 28, 2022

Companies Reporting Before The Bell • TAL Education (NYSE:TAL) is projected to report quarterly earnings at $0.01 per share on revenue of $242.62 million.

Via Benzinga

Sanofi's Earnings Outlook ↗

October 27, 2022

Sanofi (NASDAQ:SNY) is set to give its latest quarterly earnings report on Friday, 2022-10-28. Here's what investors need to know before the announcement. Analysts estimate that Sanofi will report an...

Via Benzinga

3 Dividend Stocks That Could Soar 51% to 58%, According to Wall Street ↗

October 24, 2022

Two of these three pay especially attractive dividends.

Via The Motley Fool

US Stock Futures Lower Following Friday's Rally; Tesla In Focus ↗

October 24, 2022

Pre-open movers U.S. stock futures traded lower in early pre-market trade on Monday after recording sharp gains in the previous session. The Dow Jones jumped by around 750 points on Friday. All the...

Via Benzinga

New Drugs Approvals Bring No Relief for Ailing Innovent Bio ↗

October 18, 2022

Key Takeaways: Innovent Bio has brought several drugs to market in recent years, including two announced last week, but is still losing money with no profits in sight The company has overhauled its...

Via Benzinga

2 High-Yielding Dividend Stocks That Haven't Been This Cheap in Years ↗

October 14, 2022

Is now the time to buy Sanofi and Intel?

Via The Motley Fool

3 Red-Hot Stocks That Could Continue to Beat the Market ↗

October 13, 2022

Investors are betting on these companies' revenue growth prospects.

Via The Motley Fool

Sanofi - Regeneron Tout Additional Positive Data From Flagship Dupixent Product ↗

October 11, 2022

Via Benzinga

2 Top Healthcare Stocks to Buy Right Now ↗

October 08, 2022

Healthcare is about as sticky of a business model as you'll find.

Via The Motley Fool

7 Under-$50 Stocks to Buy to Tap Into a Hidden Bull Market ↗

October 07, 2022

Those seeking compelling market ideas during this storm may want to consider these relevant under-$50 stocks to buy.

Via InvestorPlace

2 Stocks Jumping in Thursday's Premarket Trading ↗

October 06, 2022

Get an early start on the events of the day.

Via The Motley Fool

Sanofi, Provention Bio Ink Co-Promotion Pact For Type 1 Diabetes Treatment Candidate ↗

October 06, 2022

Via Benzinga

Regeneron-Sanofi's Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis ↗

September 29, 2022

Via Benzinga

Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test ↗

September 23, 2022

Though successful in early testing, it wasn't enough to win a Phase 3 study.

Via Investor's Business Daily

NASDAQ:SNY Investor Alert: Investigation over Potential Wrongdoing at Sanofi ↗

September 20, 2022

San Diego, CA -- (SBWIRE) -- 09/20/2022 -- An investigation on behalf of investors in shares of Sanofi (NASDAQ:SNY) was announced over potential breaches of fiduciary duties by certain directors at...

Via SBWire

Haleon Shares Pop After Rejecting Zantac Indemnification Requests From GSK, Pfizer ↗

September 20, 2022

Via Benzinga

Multiple Sclerosis Is A Crowded Space, But This Stock Is A Potential 6X Multi-bagger ↗

September 19, 2022

Via Benzinga

AstraZeneca's COVID-19 Antibody Cocktail, RSV Treatment For Infants Gets European Authority Backing ↗

September 16, 2022

Via Benzinga

ASLAN Pharma Starts Eblasakimab Program In Dupixent Treated Dermatitis Patients ↗

September 14, 2022

Via Benzinga

Regeneron-Sanofi Eczema Drug Shows Improvements In Itchy Inflammatory Skin Disease ↗

September 08, 2022

Via Benzinga

Sanofi-GSK COVID-19 Vaccine May See European Approval Soon: Report ↗

September 06, 2022

Via Benzinga

Sanofi-Regeneron's Flagship Drug Shows Consistent Efficacy, Safety Profile At Two Years For Asthma In Kids ↗

September 06, 2022

Via Benzinga

Top Financial Stories Thursday, September 1: Netflix Weighs Charging High Sum For Ads, Self Harm posts Grow On Twitter, California Fast-Food Bill Faces Industry Backlash... ↗

September 01, 2022

Wall Street Journal

Via Benzinga

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

39 40 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.